



NOTICE TO MEMBERS

No. 2013 - 149

June 3, 2013

FINAL CONTRACT ADJUSTMENT Resverlogix Corp. (RVX) Spin-Off (Final)

THE FOLLOWING INFORMATION IS PREPARED FOR THE CONVENIENCE OF CANADIAN DERIVATIVES CLEARING CORPORATION (CDCC) MEMBERS AND BOURSE DE MONTRÉAL INC. (THE BOURSE) APPROVED PARTICIPANTS. THIS DOCUMENT IS AN UNOFFICIAL SUMMARY OF CERTAIN TERMS OF THE AFOREMENTIONED ADJUSTMENT. CDCC AND THE BOURSE ACCEPT NO RESPONSIBILITY FOR THE ACCURACY OR COMPLETENESS OF THE SUMMARY. CDCC MEMBERS AND BOURSE APPROVED PARTICIPANTS MUST ENSURE THEY HAVE REVIEWED THE DOCUMENTATION PUBLISHED BY THE ISSUERS INVOLVED IN THIS CORPORATE ACTION.

The Bourse and CDCC wish to inform you that Resverlogix Corp. (« Resverlogix ») announced on May 28, 2013 that shareholders approved a plan of arrangement for a Spin-Off that will be effective on June 3, 2013. Holders of common shares of Resverlogix of record as of the close of business on Friday, May 31, 2013 will receive one common share of Zenith Epigenetics Corp., a newly-incorporated company (« Newco »), for each Resverlogix share held. Resverlogix shares (RVX) are trading on a “due bill” basis from the opening on May 29, 2013 until the close of markets on June 3, 2013 inclusively. Accordingly, ex-distribution trading will commence on the Toronto Stock Exchange (TSX) at the opening on June 4, 2013.

Since the Newco shares will not be listed immediately on any exchange upon completion of the plan of arrangement, CDCC will delay the time of settlement of the Newco portion of the delivery in accordance with the terms provided in Section B-404 *"Obligation to Deliver"* of the Rules of CDCC. Therefore, only RVX shares will be submitted for delivery until the Newco Share's value is ascertained. By invoking Section B-404 *"Obligation to Deliver"*, CDCC is relieving Clearing Members of their obligations to deliver and/or take receipt of the deliverable basket until further notice.

Please also note that only closing transactions will be permitted on the adjusted class.



Resverlogix Corp. (RVX)

CDCC - Adjustment Details:

Pursuant to Terms of Adjustment provided in Section A-902 of the Rules of CDCC, all Resverlogix options will be adjusted as follows:

- **EFFECTIVE DATE:** **June 4, 2013**
- **OPTIONS SYMBOL:** **RVX will become RVX1**
- **NUMBER OF CONTRACTS:** **Unchanged**
- **MULTIPLIER:** **100**
- **NEW DELIVERABLE PER CONTRACT:** **100 common shares of Resverlogix Corp. (Symbol: RVX) and 100 common shares of Newco.**
- **STRIKE PRICES:** **Unchanged**
- **POSITION AND EXERCISE LIMITS:** **The position and exercise limits will be fixed at 50,000 contracts.**
- **CUSIP :** **NOTACUSIP**

* The current Resverlogix (RVX) shares will trade under the current CUSIP: 76128M 10 8. No CUSIP is assigned to Newco.

CDCC will not accept escrow receipts on these adjusted series

Bourse de Montréal Inc. - Adjustment Details:

It is important to note that on the effective date mentioned above, all open orders on this option class **will not be automatically modified** to reflect the spin-off and will therefore have to **be re-entered** into the Montreal Automated System (SAM) by the approved participants.

The existing series of RVX options class will be transferred to the RVX1 options class representing the new deliverable. Please note that only closing transactions will be permitted on the adjusted class. Actual series that do not have open interest will not be adjusted. Please also note that the Auto-Exercise function will not be used for Resverlogix (RVX).



Resverlogix Corp.		
Actual Strike Prices	Actual Class Symbol	New class symbol after the plan of arrangement
\$1.50	RVX	RVX1
\$2.00	RVX	RVX1
\$2.50	RVX	RVX1
\$3.00	RVX	RVX1
\$3.50	RVX	RVX1
\$4.00	RVX	RVX1
\$5.00	RVX	RVX1

PLEASE ENSURE THAT ALL CLIENTS WHO HAVE EITHER LONG OR SHORT POSITIONS IN THIS OPTION CLASS ARE ADVISED OF THIS NOTICE.

For further information, please contact Louise Leclair, Trading Systems Analyst Market Operations, Bourse de Montréal Inc. at (514) 871-3526. CDCC clearing members may contact the Member Services Department.

Glenn Goucher
President and Chief Clearing Officer